Outcome Following Infliximab Therapy in Children With Ulcerative Colitis

Hyams, Jeffrey S.; Lerer, Trudy; Griffiths, Anne M.; Pfefferkorn, Marian D.; Stephens, Michael C.; Evans, Jonathan; Otley, Anthony; Carvalho, Ryan; Mack, David R.; Bousvaros, Athos; Rosh, Joel R.; Grossman, Andrew B.; Tomer, Gitit; Kay, Marsha; Crandall, Wallace; Oliva-Hemker, Maria; Keljo, David J.; LeLeiko, Neal S.; Markowitz, James

doi:10.1038/ajg.2009.759

Cited by 118 publications

(84 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical series in pediatric patients with moderate-severe, refractory ulcerative colitis have described very similar results to series enrolling adult patients with approximately 50% of patients avoiding a colectomy within five years of initiating infliximab [17][18][19][20][21] .…”

Section: Anti-tnf Therapies In Moderate-severe Refractory Ulcerativesupporting

confidence: 53%

The Role of Biologics in Ulcerative Colitis

Hanauer

2010

Dig Dis

View full text Add to dashboard Cite

Since the introduction of anti-TNF agents for the treatment of Crohn’s disease there has been interest in the potential for treating ulcerative colitis with biological therapies. Early observational series suggested a benefit in the setting of severe, hospitalized patients. However, the recent completion of two large multi-center, double-blind placebo-controlled trials confirmed a role for infliximab for outpatients with refractory, moderate-severe disease with evidence for clinical remissions, mucosal healing, and a reduction in colectomies. Despite this evidence, there are numerous questions remaining regarding the optimal positioning in the setting of moderate-severe disease, potential benefits of concomitant immune suppression and the need for maintenance treatment after induction therapy. Additional clinical trials have demonstrated a less profound benefit for adalimumab at similar doses that are used in Crohn’s disease. Other biological agents that have targeted T cells such as visiluzimab and abatacept were not demonstrated to be effective in controlled trials.

show abstract

Section: Anti-tnf Therapies In Moderate-severe Refractory Ulcerativesupporting

confidence: 53%

The Role of Biologics in Ulcerative Colitis

Hanauer

2010

Dig Dis

View full text Add to dashboard Cite

show abstract

“…Follow up of these cohorts also reported a drop in the rate of colectomy (67%) versus placebo (27%) [Janerot et al 2005]. Clinical series in pediatric patients with moderate to severe refractory UC have described very similar results to series enrolling adult patients with approximately 50% of patients avoiding colectomy within 5 years of initiating IFX [Hyams et al 2010;Russo et al 2009;Wilhelm et al 2008;Jakobovits et al 2007]. In the settings of severe-fulminant UC, cyclosporine has been (although controversial) described as salvage therapy for patients who have failed a course of intravenous steroids [McDonald et al 2005;Hanauer et al 2005].…”

Section: Introductionsupporting

confidence: 55%

Biologic Agents for Inflammatory Bowel Disease (The Current, the Future and the Controversy)

Issa¹

2012

Inflammation, Chronic Diseases and Cancer - Cell and Molecular Biology, Immunology and Clinical Bases

View full text Add to dashboard Cite

“…A number of studies have confirmed that infliximab is safe and effective in the treatment of IBD in children (36,37). In China, infliximab is mostly used in patients with refractory IBD.…”

Section: A B C Dmentioning

confidence: 99%